Physician profile
Michael E Ryan
NPI 1982608519
$580.50
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $442 · 2020: $41.33 · 2021: $76.67 · 2022: $20.51.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $181.35 | 2019-2020 | |
| Abbvie INC. | $97.18 | 2021-2022 | |
| Alexion Pharmaceuticals, INC. | $54.30 | 2019-2020 | |
| Adamas Pharmaceuticals, INC. | $43.81 | 2019 | |
| Emd Serono, INC. | $38.11 | 2019 | |
| Allergan, INC. | $26.53 | 2019-2020 | |
| Amgen INC. | $22.92 | 2019 | |
| Grifols USA, LLC | $22.65 | 2019 | |
| Acorda Therapeutics, INC | $19.16 | 2019 | |
| Mallinckrodt Enterprises LLC | $16.67 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $15.81 | 2019 | |
| Supernus Pharmaceuticals, INC. | $14.63 | 2019 | |
| Genentech USA, INC. | $14.25 | 2019 | |
| Ucb, INC. | $13.13 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Ryan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.